149 related articles for article (PubMed ID: 22430461)
1. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Takahashi S; Uemura H; Seeni A; Tang M; Komiya M; Long N; Ishiguro H; Kubota Y; Shirai T
Prostate; 2012 Oct; 72(14):1559-72. PubMed ID: 22430461
[TBL] [Abstract][Full Text] [Related]
2. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
Ishiguro H; Ishiguro Y; Kubota Y; Uemura H
Prostate; 2007 Jun; 67(9):924-32. PubMed ID: 17440964
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan is a potent target for prevention and treatment in human prostate cancer.
Funao K; Matsuyama M; Kawahito Y; Sano H; Chargui J; Touraine JL; Nakatani T; Yoshimura R
Oncol Rep; 2008 Aug; 20(2):295-300. PubMed ID: 18636189
[TBL] [Abstract][Full Text] [Related]
4. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
5. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
9. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
10. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
12. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
14. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
16. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
17. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
18. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
19. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
20. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
